Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 48,300 shares, a growth of 11,975.0% from the September 30th total of 400 shares. Based on an average daily trading volume, of 1,450,400 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Trading Up 1.7 %

Shares of OTLC traded up $0.00 on Friday, hitting $0.04. 106,288 shares of the stock traded hands, compared to its average volume of 148,917. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.01 and a current ratio of 0.01. The stock’s 50 day moving average is $0.02 and its two-hundred day moving average is $0.03. Oncotelic Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.05.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.